Retatrutide represents a GGG tri-agonist designed to interact with GLP-1 and GIP receptors, similar to conventional GLP-1 agonists. However, it possesses a distinctive feature by additionally activating the glucagon receptor. This unique receptor interaction amplifies glucagon production, fostering the degradation of stored fats and glycogen, ultimately elevating basal metabolism and ensuring a sustained fat loss. Its impact on GLP-1 and GIP receptors contributes to delayed gastric emptying and effective appetite management, presenting a holistic strategy in obesity research that sets it apart from conventional GLP-1 agonists.